Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19
Status:
Completed
Trial end date:
2020-04-02
Target enrollment:
Participant gender:
Summary
The mechanism of peripheral blood lymphocyte decline in COVID-19 patients is not yet clear.
However, one theory demonstrated that in the whole progression of COVID-19, the extensive
activation of poly-ADP-ribose polymerase (PARP) may reduce the cellular NAD+ and dampen the
adaptive immune system. So investigators presume that replenishing the NAD+ using
nicotinamide as the precursor may improve the lymphocyte counts and boost the adaptive immune
system. As a result, the study using nicotinamide as a kind of supportive therapy provide
further evidence of their efficiency and safety in treating lymphopenia in patients with
COVID-19.